Rigel Pharmaceuticals (RIGL)
(Delayed Data from NSDQ)
$10.53 USD
0.00 (0.00%)
Updated Jul 24, 2024 04:00 PM ET
After-Market: $10.58 +0.05 (0.47%) 7:58 PM ET
3-Hold of 5 3
C Value A Growth F Momentum C VGM
Rigel Pharmaceuticals (RIGL) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$42.83 | $150.00 | $14.50 | 306.74% |
Price Target
Based on short-term price targets offered by six analysts, the average price target for Rigel Pharmaceuticals comes to $42.83. The forecasts range from a low of $14.50 to a high of $150.00. The average price target represents an increase of 306.74% from the last closing price of $10.53.
Analyst Price Targets (6 )
Broker Rating
Rigel Pharmaceuticals currently has an average brokerage recommendation (ABR) of 2.33 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by six brokerage firms. The current ABR compares to an ABR of 2.33 a month ago based on six recommendations.
Of the six recommendations deriving the current ABR, two are Strong Buy, representing 33.33% of all recommendations. A month ago, Strong Buy represented 33.33%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 2 | 2 | 2 | 2 | 2 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 4 | 4 | 4 | 4 | 4 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 2.33 | 2.33 | 2.33 | 2.33 | 2.33 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
6/17/2024 | H.C. Wainwright & Co. | Joseph Pantginis | Strong Buy | Strong Buy |
4/26/2024 | Piper Sandler | Allison M Bratzel | Hold | Hold |
3/7/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
3/6/2024 | B. Riley Securities | Kalpit Patel | Hold | Hold |
3/6/2024 | Cantor Fitzgerald & Co | Kristen Kluska | Hold | Hold |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 2.33 |
ABR (Last week) | 2.33 |
# of Recs in ABR | 6 |
Average Target Price | $42.83 |
LT Growth Rate | NA |
Industry | Medical - Drugs |
Industry Rank by ABR | 100 of 252 |
Current Quarter EPS Est: | -0.37 |